Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels

Joel Tsevat; Karen M. Kuntz; E. John Orav; Milton C. Weinstein; Frank M. Sacks; Lee Goldman

doi:10.1067/mhj.2001.114805

Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels

Joel Tsevat
, Karen M. Kuntz
, E. John Orav
, Milton C. Weinstein
, Frank M. Sacks
, Lee Goldman

Health Policy and Management

Research output: Contribution to journal › Article › peer-review

82 Scopus citations

Abstract

Background: The objective of this study was to assess the cost-effectiveness of pravastatin therapy in survivors of myocardial infarction with average cholesterol levels. Methods: We performed a cost-effectiveness analysis based on actual clinical, cost, and health-related quality-of-life data from the Cholesterol and Recurrent Events (CARE) trial. Survival and recurrent coronary heart disease events were modeled from trial data in Markov models, with the use of different assumptions regarding the long-term benefit of therapy. Results: Pravastatin therapy increased quality-adjusted life expectancy at an incremental cost of $16,000 to $32,000 per quality-adjusted life-year gained. In subgroup analyses, the cost-effectiveness of pravastatin therapy was more favorable for patients >60 years of age and for patients with pretreatment low-density lipoprotein cholesterol levels >125 mg/dL. Results were sensitive to the cost of pravastatin and to assumptions about long-term survival benefits from pravastatin therapy. Conclusions: The cost-effectiveness of pravastatin therapy in survivors of myocardial infarction with average cholesterol levels compares favorably with other interventions.

Original language	English (US)
Pages (from-to)	727-734
Number of pages	8
Journal	American Heart Journal
Volume	141
Issue number	5
DOIs	https://doi.org/10.1067/mhj.2001.114805
State	Published - 2001

Bibliographical note

Funding Information:
Supported by a grant from Bristol-Myers Squibb. The funding agreement ensured the authors’ independence in designing the study, interpreting the data, and writing and publishing the manuscript.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.1067/mhj.2001.114805

Find It

Find It at U of M Libraries

Cite this

@article{187904c1f6ca4de8939a9fce4ff9996e,

title = "Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels",

abstract = "Background: The objective of this study was to assess the cost-effectiveness of pravastatin therapy in survivors of myocardial infarction with average cholesterol levels. Methods: We performed a cost-effectiveness analysis based on actual clinical, cost, and health-related quality-of-life data from the Cholesterol and Recurrent Events (CARE) trial. Survival and recurrent coronary heart disease events were modeled from trial data in Markov models, with the use of different assumptions regarding the long-term benefit of therapy. Results: Pravastatin therapy increased quality-adjusted life expectancy at an incremental cost of \$16,000 to \$32,000 per quality-adjusted life-year gained. In subgroup analyses, the cost-effectiveness of pravastatin therapy was more favorable for patients >60 years of age and for patients with pretreatment low-density lipoprotein cholesterol levels >125 mg/dL. Results were sensitive to the cost of pravastatin and to assumptions about long-term survival benefits from pravastatin therapy. Conclusions: The cost-effectiveness of pravastatin therapy in survivors of myocardial infarction with average cholesterol levels compares favorably with other interventions.",

author = "Joel Tsevat and Kuntz, \{Karen M.\} and Orav, \{E. John\} and Weinstein, \{Milton C.\} and Sacks, \{Frank M.\} and Lee Goldman",

note = "Funding Information: Supported by a grant from Bristol-Myers Squibb. The funding agreement ensured the authors{\textquoteright} independence in designing the study, interpreting the data, and writing and publishing the manuscript. ",

year = "2001",

doi = "10.1067/mhj.2001.114805",

language = "English (US)",

volume = "141",

pages = "727--734",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels

AU - Tsevat, Joel

AU - Kuntz, Karen M.

AU - Orav, E. John

AU - Weinstein, Milton C.

AU - Sacks, Frank M.

AU - Goldman, Lee

N1 - Funding Information: Supported by a grant from Bristol-Myers Squibb. The funding agreement ensured the authors’ independence in designing the study, interpreting the data, and writing and publishing the manuscript.

PY - 2001

Y1 - 2001

N2 - Background: The objective of this study was to assess the cost-effectiveness of pravastatin therapy in survivors of myocardial infarction with average cholesterol levels. Methods: We performed a cost-effectiveness analysis based on actual clinical, cost, and health-related quality-of-life data from the Cholesterol and Recurrent Events (CARE) trial. Survival and recurrent coronary heart disease events were modeled from trial data in Markov models, with the use of different assumptions regarding the long-term benefit of therapy. Results: Pravastatin therapy increased quality-adjusted life expectancy at an incremental cost of $16,000 to $32,000 per quality-adjusted life-year gained. In subgroup analyses, the cost-effectiveness of pravastatin therapy was more favorable for patients >60 years of age and for patients with pretreatment low-density lipoprotein cholesterol levels >125 mg/dL. Results were sensitive to the cost of pravastatin and to assumptions about long-term survival benefits from pravastatin therapy. Conclusions: The cost-effectiveness of pravastatin therapy in survivors of myocardial infarction with average cholesterol levels compares favorably with other interventions.

AB - Background: The objective of this study was to assess the cost-effectiveness of pravastatin therapy in survivors of myocardial infarction with average cholesterol levels. Methods: We performed a cost-effectiveness analysis based on actual clinical, cost, and health-related quality-of-life data from the Cholesterol and Recurrent Events (CARE) trial. Survival and recurrent coronary heart disease events were modeled from trial data in Markov models, with the use of different assumptions regarding the long-term benefit of therapy. Results: Pravastatin therapy increased quality-adjusted life expectancy at an incremental cost of $16,000 to $32,000 per quality-adjusted life-year gained. In subgroup analyses, the cost-effectiveness of pravastatin therapy was more favorable for patients >60 years of age and for patients with pretreatment low-density lipoprotein cholesterol levels >125 mg/dL. Results were sensitive to the cost of pravastatin and to assumptions about long-term survival benefits from pravastatin therapy. Conclusions: The cost-effectiveness of pravastatin therapy in survivors of myocardial infarction with average cholesterol levels compares favorably with other interventions.

UR - https://www.scopus.com/pages/publications/0035038827

UR - https://www.scopus.com/pages/publications/0035038827#tab=citedBy

U2 - 10.1067/mhj.2001.114805

DO - 10.1067/mhj.2001.114805

M3 - Article

C2 - 11320359

AN - SCOPUS:0035038827

SN - 0002-8703

VL - 141

SP - 727

EP - 734

JO - American Heart Journal

JF - American Heart Journal

IS - 5

ER -

Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this